SCHEDULE 13G/A
SCHEDULE 13G/ASchedule 13G ownership disclosure
Trevi Therapeutics Inc
Common Stock · CUSIP: 89532M101
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences Public Fund, L.P.
Shares: 8,819,620.00 · Class: 9.9%
- FHMLSP, L.P.
Shares: 8,819,620.00 · Class: 9.9%
- FHMLSP, L.L.C.
Shares: 8,819,620.00 · Class: 9.9%
- Frazier Life Sciences X, L.P.
Shares: 428,000.00 · Class: 0.5%
- FHMLS X, L.P.
Shares: 428,000.00 · Class: 0.5%
- FHMLS X, L.L.C.
Shares: 428,000.00 · Class: 0.5%
- Frazier Life Sciences XI, L.P.
Shares: 1,417,154.00 · Class: 1.6%
- FHMLS XI, L.P.
Shares: 1,417,154.00 · Class: 1.6%
- FHMLS XI, L.L.C.
Shares: 1,417,154.00 · Class: 1.6%
- James N. Topper
Shares: 10,664,774.00 · Class: 11.9%
- Patrick J. Heron
Shares: 10,664,774.00 · Class: 11.9%
- Albert Cha
Shares: 8,819,620.00 · Class: 9.9%
- James Brush
Shares: 8,819,620.00 · Class: 9.9%
- Daniel Estes
Shares: 1,417,154.00 · Class: 1.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-003984
- Form type
- SCHEDULE 13G/A
- Filer
- Frazier Life Sciences Public Fund, L.P.
- CIK
- CIK 1863769
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership